Understanding time processing in Huntington's and Alzheimer's diseases
Role of the Striatum and Hippocampus on Different Time Scales
This study is testing how people with Huntington's and Alzheimer's diseases understand and keep track of time to see if there are differences in their abilities.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 104 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Créteil) |
| Trial ID | NCT05943054 on ClinicalTrials.gov |
What this trial studies
This study investigates how patients with Huntington's disease and Alzheimer's disease process time on different scales, specifically focusing on the roles of the striatum and hippocampus. By developing time processing tasks, the study aims to compare the performance of these patients in interval timing, which is crucial for daily functioning. The research will involve symptomatic Huntington's disease gene carriers and patients with Alzheimer's disease, assessing their cognitive abilities related to time perception. The findings could enhance our understanding of cognitive deficits in these conditions and inform future therapeutic approaches.
Who should consider this trial
Good fit: Ideal candidates include symptomatic Huntington's disease gene carriers aged 18 to 90 and Alzheimer's patients aged 60 to 90 who meet specific cognitive criteria.
Not a fit: Patients with significant cognitive impairments outside the specified criteria or those not fluent in French may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved cognitive interventions for patients with Huntington's and Alzheimer's diseases.
How similar studies have performed: While the interaction between the striatum and hippocampus in time processing is a relatively novel area of investigation, previous studies have shown promising results in understanding cognitive deficits in related conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Huntington's disease gene carriers
* Patient included in the BioHD protocol
* Age from 18 to 90 years old
* Symptomatic patient
* TFC ≥ 11
* UHDRS motor\> 5
* Native language: French
* Affiliation to a social security or to another social protection
* Signature of informed consent
• Patients with Alzheimer's disease
* MMS from 20 to 26 (included)
* Age: from 60 to 90 years old
* Native language: French
* Progressive deterioration of memory reported by patient or caregiver for more than 6 months
* Profile at RL /RI 16: no significant improvement with indexing
* Episodic memory disorder isolated or associated with other cognitive disorders
* MRI: Atrophy of the median temporal lobe
* Affiliation to a social security or to another social protection
* Signature of informed consent
• Healthy subjects
* Healthy subject included in the BioHD protocol
* MMS ≥ 26
* Age from 18 to 90 years old
* Native language: French
* Affiliation to a social security or to another social protection
* Signature of informed consent
Exclusion Criteria:
* Huntington's disease gene carriers
* Intellectual deterioration preventing understanding of the protocol
* Other dementia than Huntington's disease
* Patient living alone at home
* Major depression
* Patient under legal protection
* Patient deprived of liberty
* Pregnant or breastfeeding woman, situation known to the investigator
* Inability to handle an electronic tablet
* Patients with Alzheimer's disease
* Intellectual deterioration preventing understanding of the protocol
* Patient living alone at home
* Sudden onset of memory impairment
* Early onset of the following symptoms: difficulty in walking, convulsions, changes in behavior
* Focal neurological characteristics including hemiparesis, sensory loss, visual field deficit
* Early extrapyramidal sign
* Other dementia than Alzheimer's disease
* Major depression
* Cerebrovascular disease
* Toxic, metabolic or infectious anomaly
* Patient under legal protection
* Patient deprived of liberty
* Pregnant or breastfeeding woman, situation known to the investigator
* Inability to handle an electronic tablet
* Healthy subjects
* Intellectual deterioration preventing understanding of the protocol
* Known neurological or psychiatric illness
* Patient under legal protection
* Subject deprived of liberty
* Pregnant or breastfeeding woman, situation known to the investigator
* Inability to handle an electronic tablet
Where this trial is running
Créteil
- Assistance Publique Hôpitaux de Paris - Hôpital Henri Mondor — Créteil, France (Recruiting)
Study contacts
- Study coordinator: Anne-Catherine BACHOUD-LEVI, MD, PhD
- Email: anne-catherine.bachoud-levi@aphp.fr
- Phone: 01 49 81 23 10
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.